Dr. Corey Langer Discusses Erlotinib in Advanced Non-Small Cell Lung Cancer
0 Views
administrator
07/14/23
Corey J. Langer, MD, Professor of Medicine, Hematology/Oncology Division, University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib (Tarceva) for patients with non-small cell lung cancer (NSCLC).
For more resources on lung cancer, visit http://www.onclive.com/specialty/lung-cancer
-
Category
Show more
Facebook Comments
No comments found